Yang En-Li, Wang Wu-Yin, Liu Ying-Qi, Yi Hong, Lei Aiwen, Sun Zhi-Jun
The State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Frontier Science Center for Immunology and Metabolism, Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan, 430079, China.
The Institute for Advanced Studies (IAS), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430079, China.
Adv Mater. 2025 Feb;37(5):e2413210. doi: 10.1002/adma.202413210. Epub 2024 Dec 15.
Cancer immunotherapy holds significant promise for improving cancer treatment efficacy; however, the low response rate remains a considerable challenge. To overcome this limitation, advanced catalytic materials offer potential in augmenting catalytic immunotherapy by modulating the immunosuppressive tumor microenvironment (TME) through precise biochemical reactions. Achieving optimal targeting precision and therapeutic efficacy necessitates a thorough understanding of the properties and underlying mechanisms of tumor-targeted catalytic materials. This review provides a comprehensive and systematic overview of recent advancements in tumor-targeted catalytic materials and their critical role in enhancing catalytic immunotherapy. It highlights the types of catalytic reactions, the construction strategies of catalytic materials, and their fundamental mechanisms for tumor targeting, including passive, bioactive, stimuli-responsive, and biomimetic targeting approaches. Furthermore, this review outlines various tumor-specific targeting strategies, encompassing tumor tissue, tumor cell, exogenous stimuli-responsive, TME-responsive, and cellular TME targeting strategies. Finally, the discussion addresses the challenges and future perspectives for transitioning catalytic materials into clinical applications, offering insights that pave the way for next-generation cancer therapies and provide substantial benefits to patients in clinical settings.
癌症免疫疗法在提高癌症治疗效果方面具有巨大潜力;然而,低响应率仍然是一个相当大的挑战。为了克服这一局限性,先进的催化材料通过精确的生化反应调节免疫抑制性肿瘤微环境(TME),在增强催化免疫疗法方面具有潜力。要实现最佳的靶向精度和治疗效果,需要深入了解肿瘤靶向催化材料的性质和潜在机制。本综述全面系统地概述了肿瘤靶向催化材料的最新进展及其在增强催化免疫疗法中的关键作用。它强调了催化反应的类型、催化材料的构建策略及其肿瘤靶向的基本机制,包括被动、生物活性、刺激响应和仿生靶向方法。此外,本综述概述了各种肿瘤特异性靶向策略,包括肿瘤组织、肿瘤细胞、外源性刺激响应、TME响应和细胞TME靶向策略。最后,讨论涉及将催化材料转化为临床应用的挑战和未来前景,提供的见解为下一代癌症治疗铺平了道路,并在临床环境中为患者带来实质性益处。